Jun 4 |
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
|
Jun 3 |
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
|
May 31 |
QIAGEN (QGEN) Develops Test for Research and CDx Application
|
May 30 |
QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications
|
May 23 |
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
|
May 16 |
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
|
May 16 |
Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
|
May 16 |
Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)
|
May 11 |
Analysts Have Made A Financial Statement On Myriad Genetics, Inc.'s (NASDAQ:MYGN) First-Quarter Report
|
May 9 |
Myriad Genetics First Quarter 2024 Earnings: Beats Expectations
|